Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Inteligex","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Discovery Platform","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"NurExone Biologic"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Product Type
            filter News Type

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Product Type

              Companies

              NurExone Biologic

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market

              Details:

              The collaboration aims at combining Inteligex’s more than twenty years of experience in cell-based therapies and NurExone’s innovative exosome platform to develop therapies for patients with chronic spinal cord injuries.

              Lead Product(s): Exosome-based Therapy

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Inteligex

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration January 17, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY